Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial
Journal
Clinical therapeutics
Journal Volume
44
Journal Issue
9
Pages
1203-1213
Date Issued
2022-09
Author(s)
Ma, Changsheng
Bai, Rong
Sun, Yihong
Nam, Gi-Byoung
Stewart, John
Wieloch, Mattias
Zhu, Jun
Abstract
Limited data are available on the impact of dronedarone treatment in Asian patients with atrial fibrillation (AF) or atrial flutter (AFL). This post hoc analysis evaluated the efficacy and safety of dronedarone compared with placebo in populations from Asian and non-Asian regions randomized in the ATHENA trial (A Placebo-Controlled, Double-blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of CV Hospitalization or Death From Any Cause in Patients With AF/AFL).
Subjects
Anti-arrhythmic drug; Asia; atrial fibrillation; cardiovascular disease; dronedarone
SDGs
Type
journal article